Sa. Ahrendt et al., Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma, J SURG RES, 84(1), 1999, pp. 88-93
Background. Cholangiocarcinoma is a frequent complication of primary sclero
sing cholangitis and is a leading cause of mortality in patients with this
disease. The tumor suppressor gene p16 is commonly inactivated in many neop
lasms; however, the role of p16 in the pathogenesis of cholangiocarcinoma i
s unclear. Therefore, we examined the role of p16 inactivation in the patho
genesis of cholangiocarcinoma associated with primary sclerosing cholangiti
s,
Materials and methods. Paraffin-embedded sections from PO patients who deve
loped cholangiocarcinoma in the setting of primary sclerosing cholangitis w
ere examined. Chromosomal loss at 9p21 was determined using microsatellite
analysis. Methylation of a CpG island in the promoter region of the p16 gen
e was determined using methylation-specific polymerase chain reaction. p16
inactivation was also determined using immunohistochemistry.
Results. Allelic loss at chromosome 9p21 was present in 9 of 10 tumors (90%
). Methylation of the p16 promoter was present in 2 of the 8 tumors examine
d (25%). Four of seven tumors (57%) analyzed by immunohistochemistry demons
trated an absence of p16 nuclear staining.
Conclusions. Loss of chromosome 9p21 and inactivation of the p16 tumor supp
ressor gene are common events in primary sclerosing cholangitis-associated
cholangiocarcinoma and may play a role in the high incidence of cholangioca
rcinoma in patients with primary sclerosing cholangitis. (C) 1999 Academic
Press.